Table 1.

List of the items collected from clinical charts.

ItemsDescription
DemographicsSex, race, age, duration of followup
DiagnosisAccording to the most recent international classification criteria
APS clinical manifestationsAs previously described5. Non-criteria manifestations defined as those not included in the updated classification criteria4, including cardiac: valvular disease, systolic dysfunction, pulmonary hypertension; pulmonary: acute respiratory distress syndrome, hemorrhagic alveolitis; central nervous system: transient ischemic attack, severe headache, epileptic seizures, cognitive dysfunctions, white matter lesions, transverse myelitis, movement disorders; renal: renal arterial stenosis, thrombotic microangiopathy; cutaneous: livedo reticularis, ulcers, digital gangrene, subungual splinter hemorrhages; ocular: ischemic optical neuritis; endocrinological: hyperprolactinemia, hyposurrenalism; hematological: thrombocytopenia, hemolytic anemia; osteoarticular: osteonecrosis, bone infarct.
Serologic changes*LABy coagulation assay
IgG-IgM aCLBy ELISA
IgG-IgM anti-β2-GPIBy ELISA
ANABy indirect immunofluorescence on Hep-2 cells substrate (≥ 1:160)
Anti-dsDNABy Farr ammonium sulfate precipitation technique, ELISA, and/or indirect immunofluorescence on Crithidia luciliae substrate
Anti-ENABy ELISA or by homemade counter-immunoelectrophoresis using calf and rabbit thymus and human spleen extracts
C3, C4By nephelometry and/or immunoturbidimetry and/or radial immunodiffusion
Cardiovascular risk factorsHormonal therapyEstroprogestinic pill or hormonal replacement therapy
ObesityBody mass index ≥ 30
SmokingPresent use of cigarettes
Diabetes mellitusAny previous diagnosis of diabetes or 2 glycemia tests ≥ 126 mg/dl
HypercholesterolemiaTotal cholesterol blood levels ≥ 200 mg/dl
HyperhomocysteinemiaBlood homocysteine above the normal limit
Systemic arterial hypertensionArterial blood pressure ≥ 140/90 mmHg
Inherited thrombophiliaAntithrombin or protein C or protein S deficiency, factor V Leiden or prothrombin or methylenetetrahydrofolate reductase mutation
CancerAny solid or hematological neoplasm diagnosis
TherapyEach drug taken for at least 3 mos at any point during followup
Severe comorbiditiesSevere infectionsRequiring hospitalization
Severe hemorrhagesFatal or requiring hospitalization/treatment withdrawal
CancerAny solid or hematological neoplasm diagnosis
Functional damagePermanent loss of function in any organ or system because of APS
  • ↵* Only confirmed serological positivity was considered (at least 2 determinations, for antiphospholipid antibodies at least 12 weeks apart). APS: antiphospholipid syndrome; LA: lupus anticoagulant; Ig: immunoglobulin; aCL: anticardiolipin antibodies; anti-β2-GPI: anti-β2 glycoprotein I antibodies; ANA: antinuclear antibodies; anti-ENA: antiextractable nuclear antigens antibodies; C3 and C4: complement fractions.